Tetratherix - Business Model

Different clinical needs. Different market segments. Single Tetramatrix™ platform technology.

We’ve developed a portfolio of products in multiple franchises to disrupt specific market segments of healthcare delivery. Our patient-centric approach is built on providing solutions that make access to healthcare cheaper and faster with improved clinical outcomes.

Through deliberate design focused on maximising impact, the Tetratherix flywheel is now in motion.

Accelerating our development velocity with our established safety and performance dataset, protected intellectual property and streamlined manufacturing, we develop products efficiently across different fields of medicine in parallel – the Tetratherix Flywheel.

We are an advanced manufacturing leader, built on the global supply of products derived from the Tetramatrix™ platform technology at scale.

Tetratherix has been built upon a contemporary commercial model that has been traditionally used in the technology and software industries. It involves licensing the developed products to leading medical companies as well as supplying the final derivative products to our partners for sale, distribution and further development.

Driving Health Equity through Innovation

With the flywheel in motion, product development with the Tetramatrix™ platform technology has become more efficient, leading to faster and cheaper healthcare innovations for our patients globally.

Reducing Risk with Diversified Franchises

By having multiple shots on goal across a range of market and partner opportunities, we reduce the regulatory, technical and commercial risk inherent to our peers in the medical technology industry.

Faster Path to Free Cash Flow

We deliberately utilise our partners’ global infrastructure for sales and distribution. This creates a capital-light cost structure upon which sits rapidly compounding revenue.

Enabling Cost-Effective R&D for Partners

Early integration of the Tetramatrix™ platform technology into partners’ internal development programs reduces their R&D inertia and reliance on late-stage M&A to meet their customers’ needs.

“Tetratherix is SaaS software platform thinking applied to the vast opportunity for smart medicines. I’m excited about the many applications that can be delivered over time and the impact they will have to millions of people.”
Rod Drury, Xero Founder and TTX Key Investor

Parallel product development across multiple franchises derived from our Tetramatrix™ platform technology provides us flexibility to partner at earlier stages with accretive returns that compound over time

Similar to a ‘build-to-buy’ model, we partner differently to, and at earlier stages than, traditional medtech companies. Therefore, our return profile is different and not built on expectations of an eventual acquisition. We enjoy periodic milestone payments as well as a steady flow of income from product supply - a dual revenue source brings the best of both worlds.

Staged partnership built on tight collaboration that limits risk and builds long-term sustainability

Proof of Concept

Tetratherix utilises foundational datasets of Tetramatrix™ platform technology to complete proof-of-concept studies and pilot clinical trials. Endpoints and assessment details are verified with partners throughout the process. Aligning objectives at this point ensures the derivative products are rapidly translated.

Transition to market

Tetratherix and the chosen partner work together to define regulatory strategies, reimbursement pathways and strategic product roll-out. Final product form, branding and short-term manufacturing demand form the pillars for an agreement to make regulatory submission and transition into the go-to-market stage.

In Market

Built on decades of effectively launching medical technologies into the market through their established teams, the chosen partner executes a deliberate and strategic launch program in specific geographies, including marketing clinical studies to realise steady and sustainable market penetration.